Drug Release Profile of a Novel Exenatide Long-term Drug Delivery System (OKV-119) Administered to Cats

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2024 May 18

PMID 38762728

Authors

Michael Klotsman

Wayne H Anderson

Chen Gilor

Affiliations

Soon will be listed here.

Abstract

Beneficial weight-loss properties of glucagon-like peptide-1 receptor agonists (GLP-1RA) in obese people, with corresponding improvements in cardiometabolic risk factors, are well established. OKV-119 is an investigational drug delivery system that is being developed for the long-term delivery of the GLP-1RA exenatide to feline patients. The purpose of this study was to evaluate the drug release characteristics of subcutaneous OKV-119 implants configured to release exenatide for 84 days. Following a 7-day acclimation period, five purpose-bred cats were implanted with OKV-119 protypes and observed for a 112-day study period. Food intake, weekly plasma exenatide concentrations and body weight were measured. Exenatide plasma concentrations were detected at the first measured timepoint (Day 7) and maintained above baseline for over 84 Days. Over the first 28 days, reduced caloric intake and a reduction in body weight were observed in four of five cats. In these cats, a body weight reduction of at least 5% was maintained throughout the 112-day study period. This study demonstrates that a single OKV-119 implant can deliver the GLP-1RA exenatide for a months long duration. Results suggest that exposure to exenatide plasma concentrations ranging from 1.5 ng/ml to 4 ng/ml are sufficient for inducing weight loss in cats.

References

Henry R, Rosenstock J, Logan D, Alessi T, Luskey K, Baron M . Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014; 28(3):393-8. DOI: 10.1016/j.jdiacomp.2013.12.009. View

Powell-Wiley T, Poirier P, Burke L, Despres J, Gordon-Larsen P, Lavie C . Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021; 143(21):e984-e1010. PMC: 8493650. DOI: 10.1161/CIR.0000000000000973. View

Rosenstock J, Buse J, Azeem R, Prabhakar P, Kjems L, Huang H . Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. Diabetes Care. 2017; 41(2):333-340. DOI: 10.2337/dc17-1306. View

Clark M, Hoenig M . Metabolic Effects of Obesity and Its Interaction with Endocrine Diseases. Vet Clin North Am Small Anim Pract. 2016; 46(5):797-815. DOI: 10.1016/j.cvsm.2016.04.004. View

Heymsfield S, Wadden T . Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254-266. DOI: 10.1056/NEJMra1514009. View

Kramer A, Riederer A, Fracassi F, Boretti F, Sieber-Ruckstuhl N, Lutz T . Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release. J Vet Intern Med. 2020; 34(6):2287-2295. PMC: 7694851. DOI: 10.1111/jvim.15915. View

Wall M, Cave N, Vallee E . Owner and Cat-Related Risk Factors for Feline Overweight or Obesity. Front Vet Sci. 2019; 6:266. PMC: 6709657. DOI: 10.3389/fvets.2019.00266. View

Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A . The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001; 25(8):1206-14. DOI: 10.1038/sj.ijo.0801655. View

Kopelman P . Obesity as a medical problem. Nature. 2000; 404(6778):635-43. DOI: 10.1038/35007508. View

10.

Grunvald E, Shah R, Hernaez R, Chandar A, Pickett-Blakely O, Teigen L . AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022; 163(5):1198-1225. DOI: 10.1053/j.gastro.2022.08.045. View

11.

Ryan D, Yockey S . Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017; 6(2):187-194. PMC: 5497590. DOI: 10.1007/s13679-017-0262-y. View

12.

Zoran D . Obesity in dogs and cats: a metabolic and endocrine disorder. Vet Clin North Am Small Anim Pract. 2010; 40(2):221-39. DOI: 10.1016/j.cvsm.2009.10.009. View

13.

Larsen J . Risk of obesity in the neutered cat. J Feline Med Surg. 2016; 19(8):779-783. PMC: 11104111. DOI: 10.1177/1098612X16660605. View

14.

Klotsman M, Adin C, Anderson W, Gilor C . Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats. Front Vet Sci. 2021; 8:661546. PMC: 8144329. DOI: 10.3389/fvets.2021.661546. View

15.

Day M . One Health Approach to Preventing Obesity in People and Their Pets. J Comp Pathol. 2017; 156(4):293-295. DOI: 10.1016/j.jcpa.2017.03.009. View

16.

Chandler M, Cunningham S, Lund E, Khanna C, Naramore R, Patel A . Obesity and Associated Comorbidities in People and Companion Animals: A One Health Perspective. J Comp Pathol. 2017; 156(4):296-309. DOI: 10.1016/j.jcpa.2017.03.006. View

17.

Clark M, Hoenig M . Feline comorbidities: Pathophysiology and management of the obese diabetic cat. J Feline Med Surg. 2021; 23(7):639-648. PMC: 10812123. DOI: 10.1177/1098612X211021540. View

18.

Su N, Li Y, Xu T, Li L, Kwong J, Du H . Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. Int J Cardiol. 2016; 219:293-300. DOI: 10.1016/j.ijcard.2016.06.028. View

19.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M . A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. DOI: 10.1056/NEJMoa1411892. View

20.

Scuderi M, Ribeiro Petito M, Unniappan S, Waldner C, Mehain S, McMillian C . Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus. Domest Anim Endocrinol. 2018; 65:80-89. DOI: 10.1016/j.domaniend.2018.04.003. View